Zealand Pharma may use acquisition option to beef up commercial muscle, CEO says
Should Zealand Pharma choose to exercise its options under its new financing agreement with Oberland Capital, opening up access to USD 200m, efforts to strenghten the firm's commercial business would likely be investigated, says CEO Emmanuel Dulac.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
On Tuesday, Zealand Pharma secured a USD 50m option for potential acquisitions of products or companies in a financing agreement with private investment firm Oberland Capital.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma enters USD 200m financing agreement
For subscribers
.jpg&w=384&q=75)
